APT Starts Human Trials Of Aerosolized Hydroxychloroquine For Asthma

APT Pharmaceuticals is beginning clinical studies of aerosolized hydroxychloroquine (AHCQ) for treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), rhinitis and severe acute respiratory syndrome (SARS).